ASH 2019 | TAK-079: an anti-CD38 antibody for R/R MM
Amrita Krishnan
• 7 Dec 2019
Amrita Krishnan, MD, City of Hope Medical Center, Duarte, CA, discusses the preliminary results from a Phase Ib study (NCT03439280) of TAK-079, an anti-CD38 monoclonal antibody, in patients with relapsed/refractory multiple myeloma (R/R MM). Emerging data show subcutaneous injection of TAK-079 induced objective response rate in 43% of the heavily pretreated patients with no infusion reaction and no drug-related lymphopenia or thrombocytopenia. As this is an ongoing trial, a cohort of patients who are refractory to previous anti-CD38 antibodies will enroll the study to further analyze the activity of TAK-079. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
